PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

Area of Science:

• Immunology
• Cancer Biology
• T Cell Biology

Background:

• Programmed cell death protein 1 (PD-1) receptor engagement on activated T cells is crucial in physiological and pathological settings.
• Anti-PD-1 antibody therapies are a cornerstone treatment for an increasing number of cancers.
• PD-1 expression on antigen-specific T cells correlates with their functional avidity and anti-tumor reactivity.

Purpose of the Study:

• To explore the dual significance of PD-1 expression on tumor-specific T cells.
• To discuss the complex regulation of PD-1 expression.
• To highlight opportunities for exploiting PD-1 expression in cancer immunotherapy.

Main Methods:

• Review of established knowledge on PD-1 receptor function in T cells.
• Analysis of PD-1 expression as a marker of T cell avidity and reactivity.
• Discussion of regulatory mechanisms influencing PD-1 expression in the tumor microenvironment.

Main Results:

• PD-1 engagement on T cells exhibits inhibitory functions.
• PD-1 expression levels on tumor-specific T cells reflect their potential for anti-tumor responses.
• The dual role of PD-1 presents complex regulatory challenges and therapeutic avenues.

Conclusions:

• PD-1 has a complex role in cancer immunity, acting both as an inhibitory receptor and a marker of T cell function.
• Understanding PD-1's dual significance is key to optimizing cancer immunotherapy.
• Exploiting PD-1 expression can help define, monitor, and enhance tumor-reactive T cells for therapeutic benefit.